Retatrutide: The Triple Agonist Explained

Introduction

Retatrutide is a triple-hormone receptor agonist — the broadest metabolic signalling compound in the GLP-1 class. As a professional peptide supplier UK, we provide high-grade retatrutide which targets GLP-1, GIP, and glucagon receptors simultaneously, producing a wider signalling footprint than dual or single agonists.

The Three Receptors

Retatrutide activates three distinct metabolic receptors:

1. GLP-1 (glucagon-like peptide-1) — glucose-dependent insulin secretion and appetite regulation
2. GIP (glucose-dependent insulinotropic polypeptide) — additional increin signalling
3. Glucagon — lipolysis and energy-expenditure signalling

The glucagon receptor arm is what distinguishes retatrutide from semaglutide (GLP-1 only) and tirzepatide (GIP + GLP-1). Glucagon receptor activation is associated with lipolysis and energy-expenditure pathways, adding a third dimension to the metabolic signalling profile.

Research Significance

The triple-agonist profile makes retatrutide valuable for research into:

• Energy expenditure — the glucagon arm adds thermogenesis and lipolysis signalling
• Comparative receptor studies — researchers can compare single (semaglutide), dual (tirzepatide), and triple (retatrutide) agonism
• Comprehensive metabolic signalling — all three major metabolic receptors in one compound

Comparison with Other Agonists

Compound	Receptors	Research Focus
Semaglutide	GLP-1	Glucose homeostasis, appetite
Tirzepatide	GIP + GLP-1	Dual increin signalling
Retatrutide	GLP-1 + GIP + Glucagon	Energy expenditure, triple agonism

This progression from single to dual to triple agonism allows researchers to study the incremental effects of each additional receptor pathway.

Research Use Only

All compounds discussed are for laboratory research use only. Not for human consumption, medical diagnosis, or treatment.